In Alzheimer’s disease, a protein fragment called beta-amyloid accumulates at abnormally high levels in the brain. Now researchers funded by the National Institutes
of  Health have found that in the most common, late-onset form of Alzheimer’s disease, beta-amyloid is produced in the brain at a normal rate but is not cleared, or removed from the brain, efficiently. In addition to improving the understanding  of what pathways are most important in development of Alzheimer’s pathology, these findings may one day lead to improved biomarker measures for early diagnosis  as well as a new approach to treating this devastating disorder.